1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,421 | 0,446 | 19:03 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.11.2025 | 123 | Xetra Newsboard | Das Instrument ZC0 NO0012780958 STAINL.TANKERS NK 10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.11.2025 und ex Kapitalmassnahme am 07.11.2025 The instrument ZC0 NO0012780958 STAINL.TANKERS NK... ► Artikel lesen | |
| 14.10. | Oncodesign Precision Medicine: OPM Obtains Development Grants From the Bourgogne Franche-Comté Region | 349 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 09.10. | Oncodesign Precision Medicine: OPM Publishes Its 2025 Half-Yearly Report | 318 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 25.09. | Oncodesign Precision Medicine: OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkinson's Research | 277 | Business Wire | OPM will contribute its unique expertise in kinase inhibitor development and its Nanocyclix®-derived compound OPM-201 to the LITE program OPM will leverage the LITE consortium to accelerate... ► Artikel lesen | |
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| 31.07. | Oncodesign Precision Medicine: OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position | 533 | Business Wire | The REVERT Phase 1b/2a clinical trial evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 has been submitted to the Swiss regulatory (Swissmedic) and ethics (Swiss ethics)... ► Artikel lesen | |
| 11.07. | Oncodesign Precision Medicine - Precision therapies for resistant diseases | 433 | Edison Investment Research | Oncodesign Precision Medicine (OPM) is a clinical-stage biopharmaceutical company listed on Euronext Growth Paris. OPM is developing precision medicine therapies targeting treatment-resistant and metastatic... ► Artikel lesen | |
| 17.04. | Oncodesign Precision Medicine Announces Equity Financing of up to 5 Million Euros | 365 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 03.04. | Oncodesign Precision Medicine: OPM Announces Its 2024 Annual Results and Clinical Developments | 452 | Business Wire | OPM-101: preclinical work establishing POC in immuno-oncology, end of phase 1 healthy volunteers and preparation for phase 1b/2a Reintegration of OPM-201 into OPM's portfolio of proprietary... ► Artikel lesen | |
| 24.03. | Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1 | 633 | Business Wire | OPM-101 will be evaluated in a Phase 1b/2a clinical trial, in combination with pembrolizumab, a monoclonal antibody directed against the PD-1 protein, in patients with advanced melanoma resistant... ► Artikel lesen | |
| 04.03. | Oncodesign Precision Medicine: Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors | 422 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 20.12.24 | Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers | 464 | Business Wire | Retrieval by OPM of all rights to the OPM-201 program and associated patent portfolio Confirmation of the molecule's safety in healthy volunteers
Regulatory News:
Oncodesign Precision... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,70 | +0,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PASITHEA THERAPEUTICS | 1,470 | +52,33 % | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | ||
| ARCELLX | 72,71 | -0,74 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| ADMA BIOLOGICS | 19,180 | +0,21 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 41,125 | -0,77 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 195,96 | +3,94 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| DYNE THERAPEUTICS | 21,910 | +3,50 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| HARMONY BIOSCIENCES | 35,290 | -0,76 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results | ||
| ARCUTIS BIOTHERAPEUTICS | 30,650 | -1,00 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| RECURSION PHARMACEUTICALS | 4,630 | +4,99 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI | ||
| COGENT BIOSCIENCES | 40,250 | -0,35 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| DAY ONE BIOPHARMACEUTICALS | 9,490 | +0,85 % | Day One Biopharmaceuticals stock maintains Buy rating at H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 43,110 | -0,58 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| SUMMIT THERAPEUTICS | 17,900 | +0,45 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 84,12 | +0,55 % | Inhibrx Biosciences auf Rekordhoch: Aktie erreicht 87,4 US-Dollar trotz Warnsignalen |
Das Unternehmen ONCODESIGN PRECISION MEDICINE SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,015 (-3,59 %) liegt der Kurs bei 0,403 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCODESIGN PRECISION MEDICINE SA finden Sie auf Wallstreet Online.